First-pass extracted concept

non-viral CRISPR carriers

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This paper centers on non-viral carriers used to deliver CRISPR components in vivo. The abstract frames them as transient delivery approaches for genome editing.

Source 1DOI PubMed

Resources required

Use requires CRISPR components and a non-viral delivery platform suitable for in vivo administration. The abstract does not specify particular carrier chemistries or payload formats.

Source 1DOI PubMed

What problem it solves

The approach addresses delivery of genome editing machinery without relying on viral vectors and supports hit-and-run exposure. The abstract states that transient delivery can still produce lasting therapeutic effects.

Source 1DOI PubMed

What it does not solve

The abstract does not show that non-viral carriers solve all delivery challenges, and it explicitly notes remaining key challenges. Specific failure modes are not given in the provided text.

Source 1DOI PubMed

Alternatives

The abstract contrasts non-viral delivery strategies with viral vectors that dominate conventional gene supplementation therapies and related gene therapy products.

Source 1DOI PubMed

Evidence Snippets

Non-Viral CRISPR carriers: transient delivery with lasting effects.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical landscape countsupports2026Source 1DOI PubMed

As of December 2025, 136 CRISPR trials were ongoing, including 36 based on in vivo delivery of CRISPR components.

Quoted textsource-backed

As of December 2025, 136 CRISPR trials are ongoing, including 36 based on <i>in vivo</i> delivery of CRISPR components

Claim 2mechanistic rationalesupports2026Source 1DOI PubMed

Because genome editing is permanent, prolonged expression of CRISPR machinery is not required and transient delivery can still achieve lasting therapeutic effects.

Quoted textsource-backed

Given the permanent nature of genome editing, prolonged expression of the CRISPR machinery is not required, and transient delivery nevertheless can achieve lasting therapeutic effects.

Claim 3safety rationalesupports2026Source 1DOI PubMed

Short-term availability of genome editing components is considered advantageous for reducing off-target effects in a hit-and-run fashion.

Quoted textsource-backed

short-term availability of genome editing components is rather considered advantageous to reduce the risk of off-target effects in a 'hit-and-run' fashion

Claim 4trend claimsupports2026Source 1DOI PubMed

In vivo CRISPR trials show a clear shift toward non-viral vectors.

Quoted textsource-backed

36 based on <i>in vivo</i> delivery of CRISPR components which show a clear shift towards non-viral vectors